Why Is SPYRE THERAPEUTICS I (SYRE) Stock Down Today?

Spyre Therapeutics SYRE fell 12.81 percent to $93.61 on Wednesday as a series of price target reductions and a negative update from the company's rheumatoid arthritis program weighed on investor sentiment. The stock has been under pressure following a string of downgraded analyst expectations and insider selling activity. The move reflects growing uncertainty about the company's near-term prospects despite a market cap of $9.4 billion.

What Happened

The stock's decline was triggered by news that Spyre Therapeutics' rheumatoid arthritis program failed to meet an internal benchmark. This development was reported by Benzinga and contributed to immediate selling pressure. In the same period, three major banks cut their price targets for the stock. Wedbush lowered its target to $123 from $130, Deutsche Bank reduced its target to $127 from $135, and BTIG cut its target to $121 from $132. Despite maintaining a "Buy" rating, Deutsche Bank's reduction signaled caution. The Fly and Barron's also highlighted the stock's underperformance, with the latter noting it lagged in premarket trading alongside other names like Intuit. Meanwhile, insiders including the CEO, CFO, and a director sold shares in recent days, adding to the negative momentum.

What The Data Shows

Over the last eight trading sessions, SYRE has declined 11.0 percent from $104.60 to $93.06. The stock has traded between $14.51 and $110.17 over the past 52 weeks and printed two fresh 52-week lows on August 27. Insider transactions over the last 90 days show 12 sales totaling $412.4 million, with no insider purchases. The stock's fundamentals remain weak, with a trailing twelve-month revenue decline of 100 percent and a negative EPS of -2.01. Its beta of 3.03 indicates high volatility. The stock's sentiment trend has deteriorated, dropping from 49 out of 100 over 30 days to 45 over the past seven days.

What To Watch

The company has no scheduled earnings release in the immediate outlook. Investors should monitor the breadth of analyst coverage and any further developments in the rheumatoid arthritis program.